BIODESIX INC

Biodesix reported increased revenues and a narrowed net loss for both the second quarter and first half of 2026. Q2 2026 revenues rose to $26.86 million, with net loss improving to $7.27 million. For the six months ended June 30, 2026, revenues reached $52.42 million, and net loss was $15.07 million. The company's cash position significantly improved, and total stockholders' equity turned positive to $9.14 million, primarily driven by $23.89 million in proceeds from common stock issuance.

Biodesix, Inc. announced strong financial and operating results for the second quarter ended June 30, 2026. The company delivered $26.9 million in total revenue, marking a 34% increase year-over-year, and achieved an 82% gross margin. Diagnostic Testing revenue grew 42%, driven by higher test volumes and improved average revenue per test. Biodesix also significantly improved its net loss and Adjusted EBITDA, while maintaining its full-year 2026 revenue guidance of $108-114 million.

Biodesix, Inc. announced that its leadership team will participate in Canaccord Genuity's 46th Annual Growth Conference. The team will host a fireside chat on August 12, 2026, at 3:30 PM ET, and conduct in-person 1x1 investor meetings. The presentation will be webcast live and available for replay on the company's investor relations website.

Biodesix, Inc. announced it will release its financial results for the second quarter ended June 30, 2026, after the close of trading on Wednesday, August 5. Following the release, Biodesix management will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a business update. Listeners and analysts can register for the webcast and Q&A session through dedicated links, with a replay available on the company's investor website.

Biodesix, Inc. announced that its leadership team will participate in three upcoming investor conferences in May and June 2026. These include the Craig-Hallum 23rd Annual Institutional Investor Conference, the William Blair 46th Annual Growth Stock Conference, and the TD Cowen Annual Tools/Dx Revolution. The presentation at the William Blair conference will be webcast live and available for replay.

Biodesix, Inc. held its 2026 annual meeting of stockholders on May 19, 2026, where all four proposals submitted to a vote were approved. Stockholders elected two Class III directors, Jean Franchi and Hany Massarany, to serve until the 2029 annual meeting. Additionally, the compensation of named executive officers and the frequency of advisory votes on executive compensation (favoring one year) were approved on a non-binding advisory basis. The appointment of KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2026, was also ratified.

Biodesix, Inc. announced that new real-world clinical and economic data for its Nodify Lung® testing will be presented at the American Thoracic Society (ATS) Annual Meeting from May 15-20, 2026. These presentations will highlight the clinical value and economic advantages of lung nodule management programs utilizing Nodify Lung® testing for risk stratification. The company's CEO, Scott Hutton, emphasized that the data reinforces the accelerating adoption of Biodesix's blood-based tests for earlier lung cancer detection and improved patient outcomes.

Biodesix Inc. reported a significant increase in revenue for the first quarter of 2026, rising 42.3% to $25.6 million, while narrowing its net loss to $7.8 million from $11.1 million in the prior year. The company also saw its net loss per share improve to $(0.81) from $(1.52). Cash and cash equivalents increased to $25.6 million, largely supported by $17.2 million in proceeds from the issuance of common stock through financing activities. This quarter marks a shift to positive stockholders' equity of $9.1 million from a deficit of $2.5 million at the end of 2025, despite an increase in net cash used in operating activities.

Biodesix reported strong first-quarter 2026 financial results, with total revenue reaching $25.6 million, a 42% increase year-over-year. This growth was driven by significant increases in both Diagnostic Testing revenue (+37%) and Development Services revenue (+99%). The company also improved its gross margin to 84% and reduced its net loss by 30% to $7.8 million. Based on this performance, Biodesix raised its full-year 2026 revenue guidance to $108-114 million, reflecting a 25% growth at the midpoint.